Alnylam Pharmaceuticals, Inc.

Exclusive license granted to key microRNA patents

Published in Biotech Law Weekly, November 19th, 2004

Alnylam Pharmaceuticals, Inc., (ALNY), an RNAi therapeutics company, and Isis Pharmaceuticals, Inc., (ISIS), a company focused on novel therapeutics targeting RNA, announced that they have co-exclusively licensed certain core intellectual property relating to all therapeutic uses of microRNA from the Max Planck Society.

Garching Innovation GmbH, the Society's technology transfer agency, facilitated the transaction. microRNAs are naturally expressed small RNAs that interact with components shared by the RNA-induced silencing complex (RISC).

RISC is an enzyme complex by which the RNA interference (RNAi) pathway operates. It is increasingly believed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2004-11-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry